Related Experiment Video
Updated: Jul 19, 2026
11:34
Building Up a High-throughput Screening Platform to Assess the Heterogeneity of HER2 Gene Amplification in Breast Cancers
Published on: December 5, 2017
Converting a breast cancer microarray signature into a high-throughput diagnostic test.
Annuska M Glas1, Arno Floore, Leonie J M J Delahaye
1Agendia BV, Slotervaart Medical Center 9D, Louwesweg 6, 1066 EC Amsterdam, The Netherlands. annuska.glas@agendia.com
BMC Genomics
|November 1, 2006
Summary
A new MammaPrint microarray accurately predicts breast cancer outcomes. This validated diagnostic tool uses a smaller probe set for high-throughput processing, proving reliable for patient prognosis.
Area of Science:
- Oncology
- Genomics
- Biotechnology
Background:
- A 70-gene tumor expression profile accurately predicts outcomes in young breast cancer patients.
- The original profile used microarrays not suitable for routine, high-throughput diagnostics.
Purpose of the Study:
- To develop a diagnostic tool for breast cancer prognosis.
- To translate the 70-gene profile into a high-throughput microarray format.
Main Methods:
- A custom microarray (MammaPrint) with 1,900 probes was designed.
- 162 patient samples were hybridized to the custom array for validation.
- Prognostic predictions from the custom array were compared to the original profile.
Main Results:
- The MammaPrint microarray showed extremely high correlation with the original 70-gene profile's predictions (p < 0.0001).
- The custom array demonstrated reproducibility and robustness.
Conclusions:
- Microarray technology can serve as a reliable diagnostic tool.
- The MammaPrint array is an effective tool for predicting breast cancer patient outcomes.
